Trail against hyperlipidemia Patients with high risks to Investigate the effect ON small dense ldl & idl by using middlE dosE rosuvastatin, atrovastatin, psSk-9 inhibitor(relationship of blood ANGPTL, Sortilin, miRNA and so on level) (PIONEERs in Saitama Study 3)
Not Applicable
Recruiting
- Conditions
- Hypercholesterolemia
- Registration Number
- JPRN-UMIN000018818
- Lead Sponsor
- Saitama Medical University
- Brief Summary
https://www.ncbi.nlm.nih.gov/pubmed/29951223 https://www.researchgate.net/publication/314118317_The_New_Molecular_Entity_Evolocumab_One_Kind_of_PCSK9_Inhibitor_Reduce_Plasma_Small_Size_LDL-Cholesterol_Levels_by_Using_a_New_Standardized_Method_of_Measuring_LDL_Size
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 300
Inclusion Criteria
Not provided
Exclusion Criteria
patients considered as inadequated by the investigator and doctor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method